Browsing Tag
Swedish Orphan Biovitrum
2 posts
Sobi bets on late-stage gout asset with acquisition of Arthrosi Therapeutics
Swedish Orphan Biovitrum is acquiring Arthrosi Therapeutics for $950 million to bolster its inflammation pipeline. Explore what this means for its growth trajectory.
Sobi begins avatrombopag phase 3 trial in immune thrombocytopenia in pediatrics
Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase…